GRZAN Medical Device Registration Services in Nicaragua

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

GRZAN provides end-to-end device registration services in Nicaragua, from risk classification through to post-market compliance. The work covers independent classification against the twenty-six rules of Annex B of NTON 24001:2023, preparation of sanitary registration and sanitary licence dossiers filed through Karplus, design of the five-category authorisation scheme and coordination of SAJ approval, preparation of technical evidence such as the CLV and ISO 13485, handling of VUCEN import authorisations, management of renewals and the seventeen change categories, and construction of a technovigilance system. Delivery in the Nicaraguan market is carried out jointly by the GRZAN registration team and locally licensed partners.

  • Classification comes first, because every later step depends on the class assigned.
  • Three hard platform constraints shape project scheduling as much as document readiness does.
  • Authorisations are a common precondition for every procedure, and the quota per registrador has to be planned.
  • Certificate issuance does not permit sales until the first-import inspection and release letter are complete.
  • Post-market work is scheduled from the start, including renewal, changes and vigilance.
  • Local presence is a structural requirement, met through licensed partners.

2. Legal basis

The table maps each service line to the provisions that govern it, so that the scope of the work can be checked against the instruments rather than against a service description alone.

ClassificationNTON 24001:2023, “Tecnología de la salud. Dispositivos médicos. Requisitos para el Registro Sanitario” (La Gaceta No. 192, 21 October 2024)Chapter 5, articles 3 and 4; Annex B; Annex DIndependent classification under the twenty-six rules of Annex B without reference to foreign classifications; borderline products may obtain an official classification ruling under Annex D within a maximum of ten working days
Registration and licensingNTON 24001:2023 (La Gaceta No. 192, 21 October 2024); Resolución Administrativa N° 0007/2025 (in force since 2 May 2025)Chapter 6, items 1 to 14; Chapter 7; Annex I, articles 7 to 14Preparation of sanitary registration and sanitary licence dossiers and filing through Karplus; account applications and management of the three hard constraints, namely no lending of accounts, five submissions per day and no new submission while one is in progress
Authorisation schemeNTON 24001:2023 (La Gaceta No. 192, 21 October 2024); RA 0001/2026Chapter 6, items 4, 5, 6 and 11; Annex I, article 5, item 10Design of the five-category authorisation scheme and coordination of SAJ approval; apostille or consular legalisation of foreign documents; planning of the twenty-five authorisation quota per registrador
Technical documentationNTON 24001:2023 (La Gaceta No. 192, 21 October 2024)Chapter 6, items 7 to 10, 12 and 13; Annex CCLV, ISO 13485 and assessment of MDSAP exemption, CE, electrical safety evidence chain; twelve-item product monograph; sample and family grouping planning
Import and customs clearanceRA 0020/2025; Circular ANRS-DDM-BRML-0001-03-2026Annex I, articles 7 and 8; circular points 3 and 4VUCEN account and import authorisation filing; preparation of the fifteen invoice elements and of expiry dates in dd/mm/aaaa format
Post-market complianceNTON 24001:2023 (La Gaceta No. 192, 21 October 2024)Chapters 8, 9, 10, 11 and 12; Annex FTwelve-item renewal within the nine-to-six-month window; assessment of the seventeen change categories and the five re-registration situations; construction of the technovigilance system; certificate correction and replacement
Regulatory watchAdenda Número 2026-05 (NTON 24001:2023 + Ad.01, adopted by the Comité Técnico de Reglamentación on 25 May 2026; WTO notification G/TBT/N/NIC/178/Add.1, circulated 1 June 2026); Circular ANRS-DDM-BRML-0002-06-2026 (ANRS medical device directorate, 5 June 2026)5.11; Chapter 4, SaMDAssessment of transitional compliance under Adenda 2026-05; early warning on the SaMD definition and on changes to software classification

3. Expert insights

The first point is that classification is the first gate and the one most easily got wrong. Chapter 5, article 3 requires ANRS to classify under Annex B without being constrained by a classification registered elsewhere. GRZAN’s approach is to work through the twenty-six rules, produce a written conclusion and cite the rule numbers relied on. That conclusion can be reused at renewal and at post-registration change, which avoids the same product carrying two different classes at different stages.

The second point is that three administrative resolutions moved licensing, registration, imports and authorisations online within fourteen months. Project rhythm is therefore no longer set by document preparation alone; it is also constrained by accounts, modules, the five-per-day quota and the rule against a new submission while one is in progress. GRZAN builds those three hard constraints into the scheduling model rather than leaving them to be handled as they appear.

The third point is that authorisations are a common precondition for every procedure: the three SAJ-approved documents in items 4, 5 and 6 of Chapter 6, plus item 11 where contract manufacturing is involved, form four parallel approval chains. GRZAN handles them through the online process under RA 0001/2026 and plans each registrador’s twenty-five authorisation quota at the same time.

The fourth point is that a registration certificate does not mean the product can be sold. Chapter 7, article 8 and article 14 of Annex I of RA 0007/2025 add the first-import quality inspection and the release letter after issuance, and the goods remain retained until the result is available. GRZAN schedules in five stages and manages the fifteen-working-day inspection window from the customs clearance date as its starting point.

The fifth point is Adenda 2026-05, which is rewriting the body of the rules: clause 5.11 proposes removing the primary-effect test for drug-device combinations, and Chapter 4 proposes a SaMD definition. The consultation runs to 1 July 2026. GRZAN treats the addendum as a quarterly review item and will reassess the compliance route for combination products and software devices once it is final.

The sixth point is local structure. Nicaragua requires a legal representative in the country in addition to the holder, together with a filing professional holding a código sanitario, and the definition of legal representative states expressly that the person must be established in the country. GRZAN delivers through locally licensed partners, namely importers and authorised distributors holding a Licencia Sanitaria and registradores and regentes sanitarios holding a código sanitario, which completes that chain.

4. Practical recommendations

  • Start with classification: supply the instructions for use, intended purpose and technical parameters, and produce a written classification conclusion against the twenty-six rules of Annex B.
  • Then fix the route: sanitary registration, an Annex D classification ruling, or one of the five re-registration situations in item 18 of Chapter 9.
  • Prepare the dossier item by item against the fourteen-item list of Chapter 6, and start the overseas authentication and approval of the three, or four, SAJ authorisations in parallel.
  • Work through the platform: obtain the Karplus account and modules, sequence submissions around the five-per-day and in-progress limits, and allow a correction window in pre-assessment and assessment.
  • Complete the release stage: request the first-import inspection within fifteen working days of customs clearance, support sampling, and schedule sales only after the release letter is obtained.
  • Manage the cycle: keep the five-year validity, the nine-to-six-month renewal window, the seventeen change categories and the finalisation status of Adenda 2026-05 in a long-term register.

5. Verification checklist

  • □ A written classification conclusion has been produced against the rules of Annex B, citing the rule numbers relied on.
  • □ The route is confirmed as sanitary registration, an Annex D classification ruling or re-registration under item 18 of Chapter 9.
  • □ The fourteen items of Chapter 6 are ready, and SAJ authorisations have entered overseas authentication and approval.
  • □ Karplus accounts and modules are open, and the submission sequence is set against the three hard constraints.
  • □ The first-import inspection is scheduled at fifteen working days from customs clearance, and no sales are arranged before the release letter.
  • □ Five-year validity, the renewal window, the seventeen change categories and the status of Adenda 2026-05 are in the long-term register.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Nicaraguan market. Our team manages Ministry of Health (MINSA) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail